Is Definium Therapeutics, Inc. (DFTX) Stock Poised for Further Gains After Positive Emerge Trial Update?

We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. Definium Therapeutics, Inc. (NASDAQ:DFTX) is one of the best biotech stocks on this list.

TheFly reported on June 23 that Robert W. Baird analyst Christopher Chen increased the price target on DFTX to $57 from $37 while maintaining an Outperform rating. The update followed the company’s Emerge trial results, which prompted the firm to revise its valuation model.

Separately, on June 22, Definium Therapeutics, Inc. (NASDAQ:DFTX) announced positive topline findings from the Emerge Phase 3 study evaluating DT120 ODT 100 microgram as a single-dose treatment in adults with major depressive disorder. The randomized, double-blind, placebo-controlled trial achieved its primary endpoint, showing a statistically significant and clinically meaningful improvement in depressive symptoms based on the change in MADRS total score at Week 6. Patients receiving DT120 ODT recorded an LS mean MADRS change of -13.3 compared with -5.2 for placebo, resulting in an LS mean difference of -8.1 points. The treatment also demonstrated rapid activity, with a placebo-adjusted LS mean reduction of -14.2 points at Week 1, and maintained durable effects with a -7.3-point reduction at Week 12.

Definium Therapeutics, Inc. (NASDAQ:DFTX) is a clinical-stage biopharmaceutical company developing next-generation therapies for psychiatric and neurological disorders using psychedelic and psychoplastogenic medicine.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.